{"id":5193,"date":"2018-09-21T08:20:50","date_gmt":"2018-09-21T12:20:50","guid":{"rendered":"http:\/\/www.ipoboutique.com\/blog\/?p=5193"},"modified":"2018-09-21T08:20:50","modified_gmt":"2018-09-21T12:20:50","slug":"new-filings-updated-terms-9-21-18","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/new-filings-updated-terms-9-21-18\/","title":{"rendered":"New Filings & Updated Terms (9.21.18)"},"content":{"rendered":"

This is the latest look at the IPO Pipeline including the newest filings that have registered with the SEC in the last seven days.<\/p>\n

<\/p>\n

IPO Boutique keeps apprised of the active pipeline. Currently there are 58 active IPOs in the pipeline as of September 21, 2018. No SPACs or Unit Offerings are included. While the numbers may look diminished, we outlined why \u201clooks may be perceiving\u201d when it comes to the IPO pipeline\u00a0in this article.<\/strong><\/a><\/p>\n

\"\"<\/a><\/p>\n

NEW FILINGS<\/strong><\/p>\n

Company: Osmotica Pharmaceuticals plc<\/strong>
\nSymbol: OSMT
\nDescription: They are a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): Jefferies, Barclays, RBC
\nFiled: 9-14-18
\nListed Cash Raise: $100m<\/p>\n

Company: Anaplan, Inc.<\/strong>
\nSymbol: PLAN
\nDescription: Anaplan is pioneering the category of Connected Planning, which allows organizations to transform their businesses by making better and faster decisions.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): Goldman Sachs, Morgan Stanley, Barclays
\nCo-Manager(s): KeyBanc Capital, Canaccord Genuity, Evercore ISI, JMP Securities, Needham & Co., Piper Jaffray, SunTrust Robinson Humphrey
\nFiled: 9-14-18
\nListed Cash Raise: $100m<\/p>\n

Company: Equillium, Inc.<\/strong>
\nSymbol: EQ
\nDescription: They are a biotechnology company leveraging deep understanding of immunobiology to develop products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): Jefferies, Leerink, Stifel
\nFiled: 9-17-18
\nListed Cash Raise: $86.25m<\/p>\n

Company: SI-BONE, Inc.<\/strong>
\nSymbol: SIBN
\nDescription: They are a medical device company that has pioneered a proprietary minimally invasive surgical implant system, which they call iFuse, to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): Morgan Stanley, BofA Merrill Lynch
\nCo-Manager(s): Canaccord Genuity, JMP Securities
\nFiled: 9-20-18
\nListed Cash Raise: $97.75m<\/p>\n

TERMS ADDED<\/strong><\/span><\/p>\n

Company: LAIX Inc.<\/strong>
\nSymbol: LAIX
\nDescription: They are a leading artificial intelligence (AI) company in China that creates and delivers products and services to popularize English learning.
\nNew York.
\nTrade Date: 9\/27
\nShares: 5.75 million ADSs
\nPrice Range: $11.50-$13.50
\nUnderwriter(s): Morgan Stanley, Goldman Sachs (Asia)
\nTerms Added: 9-14-18<\/p>\n

Company: Capital Bancorp, Inc.<\/strong>
\nSymbol: CBNK
\nDescription: They are a bank holding company and a Maryland corporation, and we operate primarily through their wholly owned subsidiary, Capital Bank, N.A., a commercial-focused community bank based in the Washington, D.C. and Baltimore metropolitan areas.
\nNew York.
\nTrade Date: 9\/26
\nShares: 2.23 million
\nPrice Range: $12.50-$14.50
\nUnderwriter(s): Keefe Bruyette & Woods, Stephens Inc.
\nCo-Manager(s): Sandler O\u2019 Neill , Hovde Group
\nTerms Added: 9-17-18<\/p>\n

Company: Sutro Biopharma, Inc.<\/strong>
\nSymbol: STRO
\nDescription: They are a clinical stage drug discovery, development and manufacturing company focused on leveraging our proprietary integrated cell-free protein synthesis platform, XpressCF, to create a broad variety of optimally designed, next-generation protein therapeutics for cancer and autoimmune disorders.
\nTrade Date: 9\/27
\nShares: 5 million
\nPrice Range: $14.00-$16.00
\nUnderwriters: Cowen, Piper Jaffray
\nCo-Manager(s): JMP Securities, Wedbush PacGrow
\nTerms Added: 9-17-18<\/p>\n

Company: RA Medical Systems<\/strong>
\nSymbol: RMED
\nDescription: They are a commercial-stage medical device company leveraging our advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases.
\nTrade Date: 9\/27
\nShares: 3.33 million
\nPrice Range: $14.00-$16.00
\nUnderwriter(s): Piper Jaffray, Cantor
\nCo-Manager(s): SunTrust Robinson Humphrey, Nomura, Maxim
\nTerms Added: 9-17-18<\/p>\n

Company: Urovant Sciences<\/strong>
\nSymbol: UROV
\nDescription: They are a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions.
\nTrade Date: 9\/27
\nShares: 10 million
\nPrice Range: $14.00-$16.00
\nUnderwriter(s): J.P. Morgan, Jefferies, Cowen
\nTerms Added: 9-17-18<\/p>\n

Company: Gritstone Oncology, Inc.<\/strong>
\nSymbol: GRTS
\nDescription: They are an immuno-oncology company developing tumor-specific cancer immunotherapies to fight multiple cancer types.
\nTrade Date: 9\/28
\nShares: 6.07 million
\nPrice Range: $13.00-$15.00
\nUnderwriter(s): Goldman Sachs, Cowen, Barclays
\nCo-Manager(s): BTIG
\nTerms Added: 9-17-18<\/p>\n

Company: Entasis Therapeutics Holdings Inc.<\/strong>
\nSymbol: ETTX
\nDescription: They are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant Gram-negative bacteria.
\nNew York.
\nTrade Date: 9\/26
\nShares: 4.4 million
\nPrice Range: $16.00-$18.00
\nUnderwriter(s): Credit Suisse, BMO Capital Markets
\nCo-Manager(s): SunTrust Robinson Humphrey, Wedbush PacGrow
\nTerms Added: 9-18-18<\/p>\n

Company: CooTek (Cayman) Inc.<\/strong>
\nSymbol: CTK
\nDescription: They are a fast-growing mobile internet company. Sophisticated big data analytics and proprietary AI capability are the backbone of their business.
\nTrade Date: 9\/28
\nShares: 4.35 million ADSs
\nPrice Range: $12.00-$14.00
\nUnderwriter(s): Credit Suisse, BofA Merrill Lynch, Citigroup, KeyBanc Capital
\nTerms Added: 9-19-18<\/p>\n

Company: Upwork Inc.<\/strong>
\nSymbol: UPWK
\nDescription: They operate the largest online global marketplace that enables businesses to find and work with highly-skilled freelancers as measured by gross services volume, or GSV.
\nTrade Date: 10\/3
\nShares: 12.27 million
\nPrice Range: $10.00-$12.00
\nUnderwriter(s): Citigroup, Jefferies, RBC, Stifel, JMP Securities
\nTerms Added: 9-20-18<\/p>\n","protected":false},"excerpt":{"rendered":"

This is the latest look at the IPO Pipeline including the newest filings that have registered with the SEC in the last seven days.<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[24,1536],"tags":[],"class_list":["post-5193","post","type-post","status-publish","format-standard","hentry","category-ipo","category-subscriber-content"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/5193","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=5193"}],"version-history":[{"count":1,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/5193\/revisions"}],"predecessor-version":[{"id":5195,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/5193\/revisions\/5195"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=5193"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=5193"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=5193"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}